(R)-3-mercapto-2-(5-morpholinopentanamido)propanoic acid | 1031482-20-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-3-mercapto-2-(5-morpholinopentanamido)propanoic acid
• 英文别名: (2R)-2-(5-morpholin-4-ylpentanoylamino)-3-sulfanylpropanoic acid
• CAS: 1031482-20-8
• 化学式: C₁₂H₂₂N₂O₄S
• 分子量: 290.384
• InChiKey: CZLQYONQYNFGRB-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  79.9
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (R)-2-(5-morpholinopentanamido)-3-(tritylsulfanyl)propanoic acid 在 三氟乙酸 、 三乙基硅烷 作用下， 以 二氯甲烷 为溶剂， 反应 2.17h， 以30%的产率得到(R)-3-mercapto-2-(5-morpholinopentanamido)propanoic acid
  参考文献：
  名称：

  [EN] S-NITROSOMERCAPTO COMPOUNDS AND RELATED DERIVATIVES
  [FR] COMPOSÉS DE S-NITROSOMERCAPTO ET DÉRIVÉS APPARENTÉS

  摘要：

  本发明涉及基于巯基和S-亚硝基巯基的SNO化合物及其衍生物，以及它们在治疗正常呼吸控制缺失方面的用途，包括治疗与睡眠、肥胖、某些药物和其他医疗状况相关的呼吸暂停和低通气。

  公开号：

  WO2009151744A1

文献信息

• S-Nitrosothiol Compounds and Related Derivatives
  申请人：Mannion James C.

  公开号：US20100105685A1

  公开（公告）日：2010-04-29

  The present invention is directed to a method of treating a lack of normal breathing control including the treatment of apnea and hypoventilation associated with sleep, obesity, certain medicines and other medical conditions. In an aspect, the invention is directed to treating disordered control of breathing by administering an composition comprising a single compound which treats lack of normal breathing. In another aspect, the invention is directed to treating disordered control of breathing by administering an composition comprising a combination of two or more compounds, at least one of which treats lack of normal breathing. In an aspect, a compound is an S-nitrosylating agent.
• [EN] S-NITROSOTHIOL COMPOUNDS AND RELATED DERIVATIVES<br/>[FR] COMPOSÉS DE S-NITROSOTHIOL, ET DÉRIVÉS ASSOCIÉS
  申请人：GALLEON PHARMACEUTICALS INC

  公开号：WO2008066603A2

  公开（公告）日：2008-06-05

  [EN] The present invention is directed to a method of treating a lack of normal breathing control including the treatment of apnea and hypoventilation associated with sleep, obesity, certain medicines and other medical conditions. In an aspect, the invention is directed to treating disordered control of breathing by administering an composition comprising a single compound which treats lack of normal breathing. In another aspect, the invention is directed to treating disordered control of breathing by administering an composition comprising a combination of two or more compounds, at least one of which treats lack of normal breathing. In an aspect, a compound is an S-nitrosylating agent.
  [FR] L'invention concerne un procédé de traitement du manque de contrôle normal de la respiration qui comprend le traitement de l'apnée et de l'hypoventilation associées au sommeil, à l'obésité, à certains médicaments et à d'autres troubles médicaux. Selon un aspect, l'invention concerne le traitement du contrôle désordonné de la respiration en administrant une composition qui comporte un simple composé qui traite le manque de respiration normale. Selon un autre aspect, l'invention concerne le traitement du contrôle désordonné de la respiration en administrant une composition qui comporte une combinaison de deux composés, ou plus, dont au moins un traite le manque de respiration normale. Selon un aspect, un composé est un agent de S-nitrosylation.